Phosphoserine phosphatase activity is elevated and correlates negatively with plasma d-serine concentration in patients with schizophrenia

Psychiatry Research

Volumn 237, Issue , 2016, Pages 344-350

  Ozeki, Yuji ^a,b   Sekine, Masae ^c   Fujii, Kumiko ^a   Watanabe, Takashi ^a   Okayasu, Hiroaki ^a   Takano, Yumiko ^a   Shinozaki, Takahiro ^a   Aoki, Akiko ^a   Akiyama, Kazufumi ^a   Homma, Hiroshi ^c   Shimoda, Kazutaka ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^c KITASATO UNIVERSITY   (Japan)

Author keywords

L serine synthesis; N methyl D aspartate receptor (NMDAR) hypofunction hypothesis; PHGDH; PSAT1; PSP

Indexed keywords

AMINOTRANSFERASE; DEXTRO AMINO ACID OXIDASE; GLUTAMIC ACID; GLUTAMINE; GLYCINE; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHOSPHATASE; PHOSPHOGLYCERATE DEHYDROGENASE; PHOSPHOSERINE AMINOTRANSFERASE 1; PHOSPHOSERINE PHOSPHATASE; RACEMASE; SERINE; SERINE RACEMASE; UNCLASSIFIED DRUG; NEUROLEPTIC AGENT;

ACTB GENE; ADULT; AMINO ACID ANALYSIS; AMINO ACID BLOOD LEVEL; AMINO ACID SYNTHESIS; ARTICLE; CONTROLLED STUDY; DAO GENE; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION REGULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHGDH GENE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSAT1 GENE; PSP GENE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SEX DIFFERENCE; SR GENE; BLOOD; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PHOSPHORIC MONOESTER HYDROLASES; SCHIZOPHRENIA; SERINE;

EID: 84959137621     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2016.01.010     Document Type: Article

References (36)

1. Akaike H. A new look at statistical model identification. IEEE Trans. Autom. Control. 1974, 19:716-723.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition 2013, American Psychiatric Publishing, Arlington.
3. Brouwer A., Luykx J.J., van Boxmeer L., Bakker S.C., Kahn R.S. NMDA-receptor coagonists in serum, plasma, and cerebrospinal fluid of schizophrenia patients: a meta-analysis of case-control studies. Neurosci. Biobehav. Rev. 2013, 37:1587-1596.
4. Calcia M.A., Madeira C., Alheira F.V., Silva T.C., Tannos F.M., Vargas-Lopes C., Goldenstein N., Brasil M.A., Ferreira S.T., Panizzutti R. Plasma levels of d-serine in Brazilian individuals with schizophrenia. Schizophr. Res. 2012, 142:83-87.
5. Chumakov I., Blumenfeld M., Guerassimenko O., Cavarec L., Palicio M., Abderrahim H., Bougueleret L., Barry C., Tanaka H., La Rosa P., Puech A., Tahri N., Cohen-Akenine A., Delabrosse S., Lissarrague S., Picard F.P., Maurice K., Essioux L., Millasseau P., Grel P., Debailleul V., Simon A.M., Caterina D., Dufaure I., Malekzadeh K., Belova M., Luan J.J., Bouillot M., Sambucy J.L., Primas G., Saumier M., Boubkiri N., Martin-Saumier S., Nasroune M., Peixoto H., Delaye A., Pinchot V., Bastucci M., Guillou S., Chevillon M., Sainz-Fuertes R., Meguenni S., Aurich-Costa J., Cherif D., Gimalac A., Van Duijn C., Gauvreau D., Ouellette G., Fortier I., Raelson J., Sherbatich T., Riazanskaia N., Rogaev E., Raeymaekers P., Aerssens J., Konings F., Luyten W., Macciardi F., Sham P.C., Straub R.E., Weinberger D.R., Cohen N., Cohen D. Genetic and physiological data implicating the new human gene G72 and the gene for d-amino acid oxidase in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:13675-13680.
6. Coyle J.T., Basu A., Benneyworth M., Balu D., Konopaske G. Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. Handb. Exp. Pharmacol. 2012, 2012:267-295.
7. Danysz W., Parsons C.G. Glycine and n-methyl-d-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol. Rev. 1998, 50:597-664.
8. de Koning T.J., Klomp L.W. Serine-deficiency syndromes. Curr. Opin. Neurol. 2004, 17:197-204.
9. Fujii K., Maeda K., Hikida T., Mustafa A.K., Balkissoon R., Xia J., Yamada T., Ozeki Y., Kawahara R., Okawa M., Huganir R.L., Ujike H., Snyder S.H., Sawa A. Serine racemase binds to PICK1: potential relevance to schizophrenia. Mol. Psychiatry 2006, 11:150-157.
10. Gonzalez-Burgos G., Lewis D.A. NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. Schizophr. Bull. 2012, 38:950-957.
11. Hamase K., Homma H., Takigawa Y., Fukushima T., Santa T., Imai K. Regional distribution and poostnatal changes of d-amino acids in rat brain. Biochim. Biophys. Acta 1997, 1334:214-222.
12. Hart C.E., Race V., Achouri Y., Wiame E., Sharrard M., Olpin S.E., Watkinson J., Bonham J.R., Jaeken J., Matthijs G., Van Schaftingen E. Phosphoserine aminotransferase deficiency: a novel disorder of the serine biosynthesis pathway. Am. J. Hum. Genet. 2007, 80:931-937.
13. Harvey R.J., Yee B.K. Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat. Rev. Drug. Discov. 2013, 12:866-885.
14. Hashimoto K. Glycine transporter-1: A new potential therapeutic target for schizophrenia. Curr. Pharm. Des. 2011, 17:112-120.
15. Hashimoto K., Engberg G., Shimizu E., Nordin C., Lindstrom L.H., Iyo M. Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog. Neuro -Psychopharmacol. Biol. Psychiatry 2005, 29:767-769.
16. Hashimoto K., Fukushima T., Shimizu E., Komatsu N., Watanabe H., Shinoda N., Nakazato M., Kumakiri C., Okada S., Hasegawa H., Imai K., Iyo M. Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the n-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry 2003, 60:572-576.
17. Hons J., Vasatova M., Cermakova E., Doubek P., Libiger J. Different serine and glycine metabolism in patients with schizophrenia receiving clozapine. J. Psychiatry Res. 2012, 46:811-818.
18. Hurvich C.M., Tsai C.L. Model selection for extended quasi-likelihood models in small samples. Biometrics 1995, 51:1077-1084.
19. Irani D.N. Properties and composition of Normal CSF. Cerebrospinal fluid 2009, 69-89. Elsevier Inc, Cambridge. D.N. Irani (Ed.).
20. Jaeken J., Detheux M., Van Maldergem L., Foulon M., Carchon H., Van Schaftingen E. 3-Phosphoglycerate dehydrogenase deficiency: an inborn error of serine biosynthesis. Arch. Dis. Child. 1996, 74:542-545.
21. Javitt D.C. Glycine transport inhibitors in the treatment of schizophrenia. Handb. Exp. Pharmacol. 2012, 2012:367-399.
22. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148:1301-1308.
23. Kantrowitz J.T., Javitt D.C. n-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?. Brain Res. Bull. 2010, 83:108-121.
24. Katane M., Osaka N., Matsuda S., Maeda K., Kawata T., Saitoh Y., Sekine M., Furuchi T., Doi I., Hirono S., Homma H. Identification of novel d-amino acid oxidase inhibitors by in silico screening and their functional characterization in vitro. J. Med. Chem. 2013, 56:1894-1907.
25. Kawazoe T., Park H.K., Iwana S., Tsuge H., Fukui K. Human d-amino acid oxidase: An update and review. Chem. Rec. 2007, 7:305-315.
26. Lane H.Y., Lin C.H., Green M.F., Hellemann G., Huang C.C., Chen P.W., Tun R., Chang Y.C., Tsai G.E. AdD-on treatment of benzoate for schizophrenia: A randomized, double-blind, placebo- controlled trial of d-amino acid oxidase inhibitor. J. Am. Assoc. Psychiatry 2013, 70:1267-1275.
27. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
28. Long Z., Nimura N., Adachi M., Sekine M., Hanai T., Kubo H., Homma H. Determination of d- and l-aspartate in cell culturing medium, within cells of MPT1 cell line and in rat blood by a column-switching high-performance liquid chromatogrpahic method. J. Chromatogr. B Biomed. Sci. Appl. 2001, 761:99-106.
29. Nishikawa T. Metabolism and functional roles of endogenous d-serine in mammalian brains. Biol. Pharm. Bull. 2005, 28:1561-1565.
30. Nishikawa T. Analysis of free d-serine in mammals and its biological relevance. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2011, 879:3169-3183.
31. Ohnuma T., Arai H. Significance of NMDA receptor-related glutamatergic amino acid levels in peripheral blood of patients with schizophrenia. Prog. Neuro -Psychopharmacol. Biol. Psychiatry 2011, 35:29-39.
32. Ozeki Y., Pickard B.S., Kano S., Malloy M.P., Zeledon M., Sun D.Q., Fujii K., Wakui K., Shirayama Y., Fukushima Y., Kunugi H., Hashimoto K., Muir W.J., Blackwood D.H., Sawa A. A novel balanced chromosomal translocation found in subjects with schizophrenia and schizotypal personality disorder: altered l-serine level associated with disruption of PSAT1 gene expression. Neurosci. Res. 2011, 69:154-160.
33. Tomiya M., Fukushima T., Watanabe H., Fukami G., Fujisaki M., Iyo M., Hashimoto K., Mitsuhashi S., Toyo'oka T. Alterations in serum amino acid concentrations in male and female schizophrenic patients. Clin. Chim. Acta 2007, 380:186-190.
34. Umbricht D., Alberati D., Martin-Facklam M., Borroni E., Youssef E.A., Ostland M., Wallace T.L., Knoflach F., Dorflinger E., Wettstein J.G., Bausch A., Garibaldi G., Santarelli L. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: A randomized, double-blind, proof-of-concept study. J. Am. Assoc. Psychiatry 2014, 71:637-646.
35. Wood P.L., Hawkinson J.E., Goodnough D.B. Formation of d-serine from l-phosphoserine in brain synaptosomes. J. Neurochem. 1996, 67:1485-1490.
36. Yang J.H., Wada A., Yoshida K., Miyoshi Y., Sayano T., Esaki K., Kinoshita M.O., Tomonaga S., Azuma N., Watanabe M., Hamase K., Zaitsu K., Machida T., Messing A., Itohara S., Hirabayashi Y., Furuya S. Brain-specific Phgdh deletion reveals a pivotal role for l-serine biosynthesis in controlling the level of d-serine, an n-methyl-d-aspartate receptor co-agonist, in adult brain. J. Biol. Chem. 2010, 285:41380-41390.